Key terms
About ANIX
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, and Other. The CAR-T Therapeutics segment involves the development of immuno-therapy drugs against cancer. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ANIX news
Mar 22
4:42pm ET
Anixa Biosciences Stockholders Affirm Confidence and Oversight
Mar 21
6:17am ET
Anixa Biosciences: A Buy Rating on Strong Financials and Promising Oncology Advances
Mar 18
3:06pm ET
Fly Insider: Crocs, Best Buy among week’s notable insider trades
Feb 13
12:20pm ET
Analysts Conflicted on These Healthcare Names: Anixa Biosciences (ANIX) and InMode (INMD)
Feb 12
7:32am ET
Anixa Biosciences begins dosing in second cohort of ovarian cancer CAR-T trial
Jan 23
7:58am ET
Anixa Biosciences granted ovarian cancer vaccine technology patent in Japan
Jan 04
2:07pm ET
Meet Anixa Biosciences: Fly exclusive interview with CEO Amit Kumar
Jan 04
2:00pm ET
Commercialization through large partner among Anixa goals, CEO tells The Fly
Jan 04
2:00pm ET
Anixa could begin human testing for ovarian cancer vaccine by 2025, CEO says
Jan 04
2:00pm ET
Anixa CEO says breast cancer vaccine data looking ‘incredibly promising’
Jan 04
2:00pm ET
Anixa looking to change cancer landscape with preventive vaccines, CEO says
No recent news articles are available for ANIX
No recent press releases are available for ANIX
ANIX Financials
Key terms
Ad Feedback
ANIX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ANIX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range